THEROS CancerTYPE ID® publications and
scientific presentations
Publications
Molecular Profiling of a Tumor of Unknown Origin
New England Journal of Medicine. September 7, 2006, Volume 355, Number 10, 1071-1072.
Molecular Classification of Human Cancers Using a 92-Gene Real-Time Quantitative Polymerase Chain Reaction Assay
Ma, Xiao-Jun, PhD, et. al. Archives of Pathology & Laboratory Medicine. April 2006, Volume 130, Number 4. 465–473.
Scientific presentations
Unknown Primary Cancer (UPC): Accuracy of Tissue of Origin Prediction by Molecular Profiling
American Society of Clinical Oncology Annual Meeting Poster Presentation, May/June, 2009
Psychosocial Aspects of Treating Patients with Cancer of Unknown Primary (CUP): A Survey of Oncology Social Workers
Association of Oncology Social Work Annual Conference Poster Presentation, May, 2009
Molecular Classification of Cancer: Implications for Carcinoma of Unknown Primary
“United States and Canadian Academy of Pathology meeting, AMP companion meeting, March 25, 2007
The CUP Assay: The Molecular Extension of Traditional Immunohistochemistry
College of American Pathologists Annual Meeting, US LABS/Esoterix Industry Breakfast Workshop Presentation, September 12, 2006. Howard Robin, M.D., Medical Director Laboratory Services, Sharp Metropolitan Hospitals, San Diego, CA.
Molecular Classification of 39 Cancer Subtypes with a Gene Panel: Implications for Diagnosis of Carcinoma of Unknown Primary
Association of Molecular Pathology, November 2005
Molecular Classification of 39 Cancer Subtypes with a Gene Panel: Implications for Diagnosis of Carcinoma of Unknown Primary (CUP)
College of American Pathologists, September 2005
CupPrint: Classification of Cancers of Unknown Primary from Paraffin Embedded Tissues Using Gene Expression Profiling
European Society of Medical Oncology (ESEC), June 2005
Molecular Classification of Tumor of Unknown Origin by Gene Expression from Fixed Paraffin Embedded Tissue
American Society of Clinical Oncology, June 2004
THEROS Breast Cancer IndexSM publications and scientific presentations
Publications
A Five-Gene Molecular Grade Index and HOXB13:IL17BR are Complementary Prognostic Factors in Early Stage Breast Cancer
Clinical Cancer Research, May 1, 2008
Scientific presentations
Prognostic Utility of HOXB13:IL17BR and Molecular Grade Index for Node-negative Breast Cancer Patients
San Antonio Breast Cancer Symposium Poster Presentation, December 2009
HOXB13 May Predict Response to Neoadjuvant Letrozole in Patients with Estrogen Receptor-positive Breast Cancer
San Antonio Breast Cancer Symposium Poster Presentation, December 2009
Validation of Prognostic Utility of HOXB13:IL17BR and Molecular Grade Index in Early Stage Breast Cancer
San Antonio Breast Cancer Symposium Abstract, December 2009
Molecular Grade Index (MGI) and H:I Ratio are Complementary Prognostic Factors in Breast Cancer
American Society of Clinical Oncology Poster, September 2007
THEROS H/ISM publications and scientific presentations
Publications
A Five-Gene Molecular Grade Index and HOXB13:IL17BR are Complementary Prognostic Factors in Early Stage Breast Cancer
Clinical Cancer Research, May 1, 2008
The Prognostic Biomarkers HOXB13, IL17BR, and CHDH Are Regulated by Estrogen in Breast Cancer
Wang et al. Clinical Cancer Research. November 1, 2007 13(21):6327-6334.
Exploring the Two-Gene Ratio in Breast Cancer – Independent Roles for HOXB13 and IL17BR in Prediction of Clinical Outcome
Jerevall et al. Breast Cancer Research Treatment. April 24, 2007 online publication.
HOXB13-to-IL17BR Expression Ratio is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study
Jansen M.P.H.M., et al. Journal of Clinical Oncology. February 2007 25(6):662-668.
The HOXB13:IL17BR Expression Index is a Prognostic Factor in Early-Stage Breast Cancer
Ma X, et al. Journal of Clinical Oncology. October 2006 24(28):4611-4619.
A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
Goetz, Matthew P, et al. Clinical Cancer Research. April 2006 12: 2080-2087.
A Two-Gene Expression Ratio Predicts Clinical Outcome in Breast Cancer Patients Treated with Tamoxifen
Ma X, et al. Cancer Cell 2004 5:607-616.
Scientific presentations
Molecular Grade Index (MGI) and H:I Ratio are Complementary Prognostic Factors in Breast Cancer
American Society of Clinical Oncology Poster, September 2007
HOXB13 to IL17BR Gene Expression Ratio is not Associated with Tumor Infiltrating Lymphocytes in Estrogen Positive, Node Negative Breast Cancer
American Association for Cancer Research, 2007
The HOXB13:IL17BR Index is a Prognostic Factor in Early Stage Breast Cancer
San Antonio Breast Cancer Symposium, December 2005
A Two-Gene Expression Ratio of HOXB13 and IL-17BR for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
San Antonio Breast Cancer Symposium, December 2005
THEROS MGISM publications and scientific presentations
Publications
Gene Expression Profiles of Human Breast Cancer Progression
PNAS, May 13, 2003
A Five-Gene Molecular Grade Index and HOXB13:IL17BR are Complementary Prognostic Factors in Early Stage Breast Cancer
Clinical Cancer Research, May 1, 2008
Scientific presentations:
Molecular Grade Index (MGI) and H:I Ratio are Complementary Prognostic Factors in Breast Cancer
American Society of Clinical Oncology Poster, September 2007
A Robust Five-Gene RT-PCR Molecular Grade Index Stratifies Recurrence Risk for Grade 2 Tumors, Predicts Chemo-Sensitivity and is Compatible with Formalin-Fixed Paraffin-Embedded Tissue
Miami Breast Cancer Conference Poster, February 2008
